Last reviewed · How we verify
immunization procedures
Immunization procedures stimulate the immune system to recognize and respond to specific pathogens or disease antigens, conferring protective immunity.
Immunization procedures stimulate the immune system to recognize and respond to specific pathogens or disease antigens, conferring protective immunity. Used for Infectious disease prevention (specific indication not disclosed).
At a glance
| Generic name | immunization procedures |
|---|---|
| Sponsor | Changchun Zhuoyi Biological Co., Ltd |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Immunization procedures involve the administration of vaccines or immunogenic preparations that train the adaptive immune system to generate antibodies and cellular immunity against target pathogens or disease-associated antigens. This approach enhances the body's ability to prevent infection or disease progression upon subsequent exposure to the pathogen or antigen.
Approved indications
- Infectious disease prevention (specific indication not disclosed)
Common side effects
- Injection site reaction
- Fever
- Myalgia
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence (PHASE2)
- The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions (NA)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (PHASE2)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- immunization procedures CI brief — competitive landscape report
- immunization procedures updates RSS · CI watch RSS
- Changchun Zhuoyi Biological Co., Ltd portfolio CI